Symptom orientation: More about VitaminD - A collection of scientific sources!

CONTENT

1. Symptom orientation!
2. Autism!
3. Cancer!
4. Fibromyalgia!
5. Psoriasis!
6. Multiple Sclerosis!
7. Osteomalacia!
8. More about VitaminD!

1. Symptom orientation!

General view on distraction from solutions by declaring the symptoms of the diseases to be their reasons.
https://geoarchitektur.blogspot.com/p/symptom-orientation-autism-cancer.html

Chapters of this article have been put into separate pages, but the content list and numbering of the chapters ist kept as original.

2. Autism!

Symptom orientation: Autism - A collection of scientific studies!
https://geoarchitektur.blogspot.com/p/symptom-orientation-autism-collection.html


3. Cancer

Symptom orientation: Cancer - A collection of scientific studies!

https://geoarchitektur.blogspot.com/p/symptom-orientation-cancer-collection.html

4. Fibromyalgia

Symptom orientation: Fibromyalgia - A collection of scientific studies!

https://geoarchitektur.blogspot.com/p/symptom-orientation-fibromyalgia.html

5. Psoriasis

Symptom orientation: Psoriasis - A collection of scientific studies!
https://geoarchitektur.blogspot.com/p/symptom-orientation-psoriasis.html

6. Multiple Sclerosis

7. Osteamalacia

Symptom orientation: Multiple Sclerosis - A collection of scientific studies!
https://geoarchitektur.blogspot.com/p/symptom-orientation-multiple-sclerosis.html

8. More about VitaminD

Further sources for own research!

https://organixx.com/vitamin-d-deficiency-symptoms-2/?utm_campaign=vitamin-d-deficiency-symptoms&utm_medium=email&utm_source=maropost&utm_content=2017-04-28&utm_term
https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
http://articles.mercola.com/sites/articles/archive/2014/05/28/vitamin-d-deficiency-signs-symptoms.aspx
http://www.mayoclinicproceedings.org/article/S0025-6196%2813%2900404-7/fulltext
https://health.ucsd.edu/news/releases/Pages/2016-04-06-low-vitamin-d-higher-cancer-risk.aspx
http://www.creighton.edu/publicrelations/newscenter/news/2015/march2015/march172015/heaneyrdatoolownr031715/

A very easy explanation of vitaminD deficiency, in German!

Don't poison Your skin with chemicals!



Sonnen- und Vitamin D-Mangel in der Überflussgesellschaft 
Sep 2, 2014

https://www.researchgate.net/figure/43341726_fig4_Synthesis-and-metabolism-of-hormonal-steroids-This-figure-illustrates-the-formation-of

"This figure illustrates the formation of the major hormone classes from cholesterol. Steroid names in conventional script are steroid hormones and precursors; those in italics are urinary metabolites of the aforementioned. The major transformative enzymes are in rectangular boxes, the cofactor (“facilitator”) enzymes in ovals. The pale blue area contains common intermediate steps; the yellow preliminary steps in glucocorticoid synthesis; the green mineralocorticoids; the orange, glucocorticoids; dark blue, androgens and pink, estrogens. Mitochondrial CYP type I enzymes requiring electron transfer via adrenodoxin reductase (ADR) and adrenodoxin (Adx) CYP11A1, CYP11B1, CYP11B2, are marked with a labelled box ADR/Adx. Microsomal CYP type II enzymes receive electrons from P450 oxidoreductase (POR), CYP17A1, CYP21A2, CYP19A1, are marked by circled POR. The 17,20-lyase reaction catalyzed by CYP17A1 requires in addition to POR also cytochrome b5 indicated by a circled b5. Similarly, hexose-6-phosphate dehydrogenase (H6PDH) is the cofactor-generating enzyme for 11β-HSD1. The asterisk (*) indicates the 11-hydroxylation of 17OHP to 21-deoxycortisol in 21-hydroxylase deficiency. The conversion of androstenedione to testosterone is catalyzed by HSD17B3 in the gonad and AKR1C3 (HSD17B5) in the adrenal. StAR, steroidogenic acute regulatory protein; CYP11A1, P450 side-chain cleavage enzyme; HSD3B2, 3β-hydroxysteroid dehydrogenase type 2; CYP17A1, 17α-hydroxylase; CYP21A2, 21-hydroxylase; CYP11B1, 11β-hydroxylase; CYP11B2, aldosterone synthase; HSD17B, 17β-hydroxysteroid dehydrogenase; CYP19A1, P450 aromatase; SRD5A2, 5α-reductase type 2; SULT2A1, sulfotransferase 2A1; PAPPS2, 3′-phosphoadenosine 5′-phosphosulfate synthase 2."

Vitamin D and Cardiovascular Disease
P.E. Norman, J.T. Powell
http://circres.ahajournals.org/content/114/2/379

"... Vitamin D receptors have been found in all the major cardiovascular cell types including cardiomyocytes, arterial wall cells, and immune cells. Experimental studies have established a role for vitamin D metabolites in pathways that are integral to cardiovascular function and disease, including inflammation, thrombosis, and the renin–angiotensin system. Clinical studies have generally demonstrated an independent association between vitamin D deficiency and various manifestations of degenerative cardiovascular disease including vascular calcification. However, the role of vitamin D supplementation in the management of cardiovascular disease remains to be established. This review summarizes the clinical studies showing associations between vitamin D status and cardiovascular disease and the experimental studies that explore the mechanistic basis for these associations."

VITAMIN D – HEILMITTEL FÜR MS UND AUTOIMMUNERKRANKUNGEN?
"Interview mit Dr Coimbra über hochdosiertes Vitamin D für Multiple Sklerose und andere Autoimmunerkrankungen: Das Coimbra Protokoll. Erfolgsquote 95 Prozent."
http://www.vitamind.net/interviews/coimbra-ms-autoimmun/

"Die tägliche Dosis, die heute international empfohlen wird, ist eine armselige Dosis, weit unter der physiologischen Dosis. Die physiologische Dosis beträgt – wie kürzlich belegt wurde – minimal 7.000 Tageseinheiten für Erwachsene mit einem normalen Body-Mass-Index, die gleiche Menge, die der Körper in nur 10 bis 20 Minuten der Exposition gegenüber der Sonne produzieren kann – abhängig vom Ausmaß der exponierten Körperoberfläche, der Körperposition (liegend oder stehend), der Pigmentierung der Haut, Alter und dem Sonnenstand."

"10.000 IE sind also eine physiologische Dosis, keine Super-Dosis."

"Beeindruckt von diesem ersten Ergebnis begann ich, die 10.000 Einheiten Vitamin D auch bei Patienten mit Multipler Sklerose zu geben. MS ist eine sehr häufige Autoimmunerkrankung in der Neurologie, mit sehr verheerenden Auswirkungen. Diese erste tägliche Dosis gaben wir auch bei anderen Autoimmunerkrankungen wie Psoriasis, Lupus, rheumatoider Arthritis. Wir waren erstaunt, zu sehen, wie viel besser es diesen Patienten ging, obwohl sie nicht völlig symptomfrei wurden. Aber das war der Ausgangspunkt: die Anerkennung des großen Wertes von Vitamin D bei der Behandlung von Autoimmunerkrankungen."

"Vitamin D ist der größte Regulator des Immunsystems und modifiziert die Funktion von Tausenden von Genen in jeder Zelle des Immunsystems. Es ist eine Substanz, zu der es keine vergleichbare Zweite gibt."

"Bei einem Vitamin-D-Mangel kann der Kranke die Aktivität von Tausenden von biologischen Funktionen innerhalb der Zellen des Immunsystems nicht mehr regulieren – also stimulieren oder reduzieren – ein Mangel an dieser einen Substanz resultiert also in einer Katastrophe für das Immunsystem!"

"Menschen mit Vitamin-D-Mangel sind darum anfällig für zahlreiche Autoimmunerkrankungen wie Multiple Sklerose, Autoimmune Polyneuropathie, Guillain-Barré-Syndrom, rheumatoide Arthritis, Psoriasis-Arthritis (und Schuppenflechte selbst), Myasthenia gravis, Polymyositis und systemischem Lupus erythematosus – um nur einige zu nennen."

Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial.
Li L1, Lin M1, Krassilnikova M1, Ostrow K1, Bader A1, Radbill B1, Uribarri J1, Tokita J1, Leisman S1, Lapsia V1, Albrecht RA2, García-Sastre A3, Branch AD4,Heeger PS5, Mehrotra A1.
PLoS One. 2014 Oct 8;9(10):e109998. doi: 10.1371/journal.pone.0109998. eCollection 2014.
https://www.ncbi.nlm.nih.gov/pubmed/25296334

"BACKGROUND:

Memory T-cells are mediators of transplant injury, and no therapy is known to prevent the development of cross-reactive memory alloimmunity. Activated vitamin D is immunomodulatory, and vitamin D deficiency, common in hemodialysis patients awaiting transplantation, is associated with a heightened alloimmune response. Thus, we tested the hypothesis that vitamin D3 supplementation would prevent alloreactive T-cell memory formation in vitamin D-deficient hemodialysis patients."

"METHODS AND FINDINGS:

We performed a 12-month single-center pilot randomized, controlled trial of 50,000 IU/week of cholecalciferol (D3) versus no supplementation in 96 hemodialysis patients with serum 25(OH)D<25 104.8="" 1="" 252.9="" 25="" 2:1="" 42.5="" 6="" active="" alloreactive="" and="" assays="" at="" between="" but="" changes="" compared="" control.="" control="" controls="" d3="" delta="" demonstrated="" did="" duration="" effects="" either="" elispot-based="" episodes="" for="" functional="" greater="" group.="" group="" groups="" hypercalcemia="" ifn="" in="" increased="" increases="" measuring="" memory="" ml="" ng="" no="" not="" occurred="" of="" on="" over="" p="0.25).</i" panel="" participants="" phenotypic="" properties="" prt="" quantifying="" randomized="" reach="" reactive="" results="" serum="" significance="" statistical="" study.="" supplementation="" sustained="" t-cell="" t-cells.="" the="" these="" to="" treatment="" versus="" vs="" weeks="" were="" year="">"

"CONCLUSIONS:

D3 supplements are safe, effective at treating vitamin D deficiency, and may prevent time-dependent increases in T-cell alloimmunity in hemodialysis patients, but their effects on alloimmunity need to be confirmed in larger studies. These findings support the routine supplementation of vitamin D-deficient transplant candidates on hemodialysis and highlight the need for large-scale prospective studies of vitamin D supplementation in transplant candidates and recipients."

Low Dietary Intake of Vitamin D and Vitamin D Deficiency in Hemodialysis Patients.
2014 May 15;4(3). pii: 166.
Krassilnikova M1, Ostrow K1, Bader A1, Heeger P1, Mehrotra A1.
J Nephrol Ther.

"BACKGROUND:

The purpose of this study was to test the hypothesis that decreased dietary intake of Vitamin D contributes to Vitamin Ddeficiency in end-stage renal disease (ESRD) patients on hemodialysis (HD)."

"METHODS:

We performed a cross-sectional study of 58 hemodialysis outpatients from two Mount Sinai Medical Center (MSMC)-affiliated outpatient HD units in New York City and 648 outpatients at MSMC with CKD stages I-IV. Serum 25(OH)D concentrations were measured from August 2010 to July of 2011 in recruited hemodialysis patients (n=58) and linked with results of dietary and lifestyle surveys. The Mount Sinai Data Warehouse (electronic medical record) was used to capture 25(OH) Vitamin D levels for outpatients with CKD stages I-IV who hadVitamin D testing during the same time period."

"RESULTS:

The prevalence of Vitamin D insufficiency/deficiency in the HD cohort was 96.6%. Mean (SD) and median (IQR) 25(OH)D concentrations were 15.65 (6.82) and 13.55 (10.15) ng/mL, respectively. Dietary surveys showed a median weekly Vitamin D intake of 1044 IU (IQR=808, vs. a recommended weekly allowance of 4200 IU) and specific avoidance of foods containing both Vitamin D and phosphorus. In contrast, mean and median 25(OH)D concentrations in patients with CKD stages I-IV were 25.66 (13.44) and 23.60 (15.48) ng/mL (p<0 .001="" hd="" i="" patients="" vs.="">"

"CONCLUSIONS:

Vitamin D deficiency is more prevalent in HD patients than in pre-dialysis patients with CKD and is associated with decreased dietary intake of Vitamin D. Dialysis restrictions imposed to reduce dietary phosphorus intake likely contributes to the development of hypovitaminosis D in ESRD patients."